Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
inbiome
Amsterdam, North Holland, Netherlands
- Ownership
- Private
- Development stage
- Other
01
Overview
Molecular Culture ID enables same-day, highly accurate identification of over 200 bacterial species from patient samples, reducing diagnostic time from days to hours and improving both outcomes and antimicrobial stewardship; FDA Breakthrough Device Designation granted 2024 for infectious disease diagnostics[3].
- Therapeutic areas
- Infectious DiseasesGastroenterology
- Modalities
- DeviceMolecular Technology Platform
- Industry
- Molecular Diagnostics
02
Partnerships
European Innovation Council (EIC)Academic partnerships with universities and hospitals (including Maastricht University Medical Centre)
Beyond the preview
Go deeper on inbiome.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on inbiome.